Sumitomo Chemical has launched SC-AMSA in Marlborough, Massachusetts, to expand its oligonucleotide CDMO business, supplying long-chain gRNA for genome editing by August 2025.

Massachusetts, United States: Sumitomo Chemical has announced the establishment of Sumitomo Chemical Advanced Medical Solutions America LLC (“SC-AMSA”) in Marlborough, Massachusetts, reinforcing its commitment to the oligonucleotide contract development and manufacturing organization (CDMO) business. The new entity will function as a contract research organization (CRO), facilitating the development and commercialization of nucleic acid-based drug substances. SC-AMSA aims to begin supplying gRNA samples to customers by August 2025.

Sumitomo Chemical has been active in the nucleic acid drug substance CDMO sector since 2013, with a growing focus on the large-scale production of long-chain oligonucleotides, particularly guide RNA (gRNA) for genome editing therapies. The company has developed a pioneering technology that enables the scalable production of long-chain gRNA, approximately 100 mer in length, with a high purity of around 90% and exceptional yield. A new manufacturing plant at Sumitomo Chemical’s Oita Works in Japan commenced shipments to multiple customers in fiscal 2024.

The strategic selection of Marlborough, located near Boston—a hub for biotech and pharmaceutical startups—will enable Sumitomo Chemical to closely engage with potential customers and swiftly respond to market needs. Through SC-AMSA, the company aims to provide high-quality gRNA solutions to support drug discovery and genome editing advancements in the U.S.

This expansion aligns with Sumitomo Chemical Group’s long-term vision of addressing critical societal challenges in the areas of food, ICT, healthcare, and the environment through innovative technologies. The Group has identified agriculture-related and ICT-related businesses as its current growth drivers, with the newly established Advanced Medical Solutions Sector positioned as the next key growth area.

According to TechSci Research, Sumitomo Chemical’s establishment of SC-AMSA in the United States marks a significant advancement in the healthcare industry, particularly in the field of genome editing and precision medicine. By focusing on the large-scale production of long-chain guide RNA (gRNA), the company is addressing the increasing demand for high-purity nucleic acid-based drug substances essential for advanced therapies.

This initiative enhances the accessibility of high-quality gRNA for drug discovery and genome editing applications, facilitating the development of innovative treatments for genetic disorders, rare diseases, and personalized medicine. Furthermore, Sumitomo Chemical’s strategic expansion into small-molecule drug CDMO services, regenerative medicine, and cell therapy signals broader advancements in biopharmaceutical manufacturing.